SAGE - Sage Therapeutics Q3 2021 Earnings Preview

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$1.86 and the consensus Revenue Estimate is $1.97M (+20.1% Y/Y). Sage shares rose more than 8% in reaction to posting a narrower second-quarter net loss and provided a cash position update, in August. In July, Seeking Alpha contributor Bret Jensen argued that Sage is showing upside but highlighted that there are plenty of unknowns. Over the last 1 year, SAGE has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 11 downward. Revenue estimates have seen 1 upward revision and 13 downward. The company's shares have fallen more than 53% year to  date.

For further details see:

Sage Therapeutics Q3 2021 Earnings Preview